{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:34:13Z","timestamp":1781652853985,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1245\/s10434-022-11869-7","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T14:03:11Z","timestamp":1652882591000},"page":"5948-5956","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts"],"prefix":"10.1245","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0923-153X","authenticated-orcid":false,"given":"Edmund K.","family":"Bartlett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Swetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sancy A.","family":"Leachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Curiel-Lewandrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Dusza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Gershenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kirkwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Tin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Vickers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"issue":"8","key":"11869_CR1","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","volume":"25","author":"JE Gershenwald","year":"2018","unstructured":"Gershenwald JE, Scolyer RA. Melanoma staging: American joint committee on cancer (AJCC) 8th edition and beyond. Ann Surg Oncol. 2018;25(8):2105\u201310. https:\/\/doi.org\/10.1245\/s10434-018-6513-7.","journal-title":"Ann Surg Oncol."},{"key":"11869_CR2","doi-asserted-by":"publisher","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al. 2017 Melanoma staging: evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 67(6):472\u201392. https:\/\/doi.org\/10.3322\/caac.21409","DOI":"10.3322\/caac.21409"},{"key":"11869_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2019.10.027","volume":"125","author":"TMS Amaral","year":"2020","unstructured":"Amaral TMS, Hoffmann MC, Sinnberg T, et al. Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. Eur J Cancer. 2020;125:38\u201345. https:\/\/doi.org\/10.1016\/j.ejca.2019.10.027.","journal-title":"Eur J Cancer."},{"issue":"5","key":"11869_CR4","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.surg.2015.12.002","volume":"159","author":"ME Egger","year":"2016","unstructured":"Egger ME, Bhutiani N, Farmer RW, et al. Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes. Surgery. 2016;159(5):1412\u201321. https:\/\/doi.org\/10.1016\/j.surg.2015.12.002.","journal-title":"Surgery."},{"issue":"5","key":"11869_CR5","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/bjs.11946","volume":"108","author":"MA El Sharouni","year":"2021","unstructured":"El Sharouni MA, Ahmed T, Witkamp AJ, et al. Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data. Br J Surg. 2021;108(5):550\u20133. https:\/\/doi.org\/10.1002\/bjs.11946.","journal-title":"Br J Surg."},{"issue":"3","key":"11869_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/bjs.10995","volume":"106","author":"D Verver","year":"2019","unstructured":"Verver D, van Klaveren D, Franke V, et al. Development and validation of a nomogram to predict recurrence and melanoma-specific mortality in patients with negative sentinel lymph nodes. Br J Surg. 2019;106(3):217\u201325. https:\/\/doi.org\/10.1002\/bjs.10995.","journal-title":"Br J Surg."},{"issue":"34","key":"11869_CR7","doi-asserted-by":"publisher","first-page":"5772","DOI":"10.1200\/JCO.2009.22.8239","volume":"27","author":"BE Gould Rothberg","year":"2009","unstructured":"Gould Rothberg BE, Berger AJ, Molinaro AM, et al. Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol. 2009;27(34):5772\u201380. https:\/\/doi.org\/10.1200\/JCO.2009.22.8239.","journal-title":"J Clin Oncol."},{"issue":"1","key":"11869_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12885-018-4016-3","volume":"18","author":"JS Zager","year":"2018","unstructured":"Zager JS, Gastman BR, Leachman S, et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer. 2018;18(1):130. https:\/\/doi.org\/10.1186\/s12885-018-4016-3.","journal-title":"BMC Cancer."},{"key":"11869_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i6","volume":"352","author":"AJ Vickers","year":"2016","unstructured":"Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. BMJ. 2016;352:i6. https:\/\/doi.org\/10.1136\/bmj.i6.","journal-title":"BMJ."},{"issue":"21","key":"11869_CR10","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1200\/jco.2015.65.5654","volume":"34","author":"KF Kerr","year":"2016","unstructured":"Kerr KF, Brown MD, Zhu K, Janes H. Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use. J Clin Oncol. 2016;34(21):2534\u201340. https:\/\/doi.org\/10.1200\/jco.2015.65.5654.","journal-title":"J Clin Oncol."},{"key":"11869_CR11","unstructured":"National Comprehensive Cancer Network Guidelines for Melanoma. Available at: https:\/\/www.nccn.org\/. Accessed 5 Jan 2022."},{"key":"11869_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1200\/po.19.00206","volume":"4","author":"D Bellomo","year":"2020","unstructured":"Bellomo D, Arias-Mejias SM, Ramana C, et al. Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma. JCO Precis Oncol. 2020;4:319\u201334. https:\/\/doi.org\/10.1200\/po.19.00206.","journal-title":"JCO Precis Oncol."},{"issue":"24","key":"11869_CR13","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1200\/JCO.19.02362","volume":"38","author":"SN Lo","year":"2020","unstructured":"Lo SN, Ma J, Scolyer RA, et al. Improved risk prediction calculator for sentinel node positivity in patients with melanoma: the melanoma institute Australia Nomogram. J Clin Oncol. 2020;38(24):2719\u201327. https:\/\/doi.org\/10.1200\/JCO.19.02362.","journal-title":"J Clin Oncol."},{"issue":"11","key":"11869_CR14","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2217\/fon-2018-0912","volume":"15","author":"JT Vetto","year":"2019","unstructured":"Vetto JT, Hsueh EC, Gastman BR, et al. Guidance of sentinel lymph node biopsy decisions in patients with T1\u2013T2 melanoma using gene expression profiling. Future Oncol. 2019;15(11):1207\u201317. https:\/\/doi.org\/10.2217\/fon-2018-0912.","journal-title":"Future Oncol."},{"issue":"9","key":"11869_CR15","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1001\/jamadermatol.2020.1729","volume":"156","author":"D Grossman","year":"2020","unstructured":"Grossman D, Okwundu N, Bartlett EK, et al. Prognostic gene expression profiling in cutaneous melanoma: identifying the knowledge gaps and assessing the clinical benefit. JAMA Dermatol. 2020;156(9):1004\u201311. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1729.","journal-title":"JAMA Dermatol."},{"issue":"10","key":"11869_CR16","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1007\/s11606-021-06737-1","volume":"36","author":"A Sharma","year":"2021","unstructured":"Sharma A, Minh Duc NT, Luu Lam Thang T, et al. A consensus-based checklist for reporting of survey studies (CROSS). J Gen Intern Med. 2021;36(10):3179\u201387. https:\/\/doi.org\/10.1007\/s11606-021-06737-1.","journal-title":"J Gen Intern Med."},{"issue":"4","key":"11869_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2401","volume":"3","author":"GS Heriot","year":"2020","unstructured":"Heriot GS, Tong SYC, Cheng AC, Liew D. A scenario-based survey of expert echocardiography recommendations for patients with staphylococcus aureus bacteremia at varying risk for endocarditis. JAMA Netw Open. 2020;3(4):e202401. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.2401.","journal-title":"JAMA Netw Open."},{"issue":"2","key":"11869_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1136\/ebmed-2014-110140","volume":"20","author":"MH Ebell","year":"2015","unstructured":"Ebell MH, Locatelli I, Senn N. A novel approach to the determination of clinical decision thresholds. Evid Based Med. 2015;20(2):41\u20137. https:\/\/doi.org\/10.1136\/ebmed-2014-110140.","journal-title":"Evid Based Med."},{"issue":"20","key":"11869_CR19","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJM198005153022003","volume":"302","author":"SG Pauker","year":"1980","unstructured":"Pauker SG, Kassirer JP. The threshold approach to clinical decision making. N Engl J Med. 1980;302(20):1109\u201317. https:\/\/doi.org\/10.1056\/NEJM198005153022003.","journal-title":"N Engl J Med."},{"issue":"4","key":"11869_CR20","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1245\/s10434-016-5642-0","volume":"24","author":"AY Lee","year":"2017","unstructured":"Lee AY, Droppelmann N, Panageas KS, et al. Patterns and timing of initial relapse in pathologic stage II melanoma patients. Ann Surg Oncol. 2017;24(4):939\u201346. https:\/\/doi.org\/10.1245\/s10434-016-5642-0.","journal-title":"Ann Surg Oncol."},{"issue":"13","key":"11869_CR21","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1056\/NEJMoa060992","volume":"355","author":"DL Morton","year":"2006","unstructured":"Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307\u201317. https:\/\/doi.org\/10.1056\/NEJMoa060992.","journal-title":"N Engl J Med."},{"key":"11869_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2020.08.029","volume":"140","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont AMM, Bellomo D, Arias-Mejias SM, et al. Identification of stage I\/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model. Eur J Cancer. 2020;140:11\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2020.08.029.","journal-title":"Eur J Cancer."},{"issue":"9","key":"11869_CR23","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamadermatol.2020.1731","volume":"156","author":"MA Marchetti","year":"2020","unstructured":"Marchetti MA, Coit DG, Dusza SW, et al. Performance of gene expression profile tests for prognosis in patients with localized cutaneous melanoma: a systematic review and meta-analysis. JAMA Dermatol. 2020;156(9):953\u201362. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1731.","journal-title":"JAMA Dermatol."},{"issue":"19","key":"11869_CR24","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u2013801. https:\/\/doi.org\/10.1056\/NEJMoa1802357.","journal-title":"N Engl J Med."},{"issue":"19","key":"11869_CR25","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017;377(19):1824\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1709030.","journal-title":"N Engl J Med."},{"issue":"12","key":"11869_CR26","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","volume":"383","author":"R Dummer","year":"2020","unstructured":"Dummer R, Hauschild A, Santinami M, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med. 2020;383(12):1139\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2005493.","journal-title":"N Engl J Med."},{"key":"11869_CR27","doi-asserted-by":"crossref","unstructured":"Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: efficacy and safety results from the Keynote 716 double-blinded phase III trial. Ann Oncol. 2021;32(Suppl\u00a05):","DOI":"10.1016\/j.annonc.2021.08.2116"},{"issue":"19","key":"11869_CR28","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017;377(19):1813\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1708539.","journal-title":"N Engl J Med."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11869-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-11869-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11869-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T17:10:04Z","timestamp":1659805804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-11869-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["11869"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-11869-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"assertion":[{"value":"17 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Susan M. Swetter, Clara Curiel-Lewandrowski, Stephen W. Dusza, Amy L. Tin, Andrew J. Vickers, and Michael A. Marchetti report no conflicts of interest. Edmund K. Bartlett reports receiving institutional research funding from SkylineDx and an honorarium from Excite International unrelated to the content of this work. Jeffrey E. Gershenwald has been on an advisory board and\/or consultant for Merck, Bristol Myers Squibb, and Regeneron in the past 24 months, unrelated to the content of this work. Douglas Grossman is an investigator for Dermtech, Inc. and Orlucent, Inc., and serves on the advisory board for Orlucent, Inc., all unrelated to the content of this work. Sancy A. Leachman receives research support from Orlucent, Inc., DermDetect, and Myriad Genetics Laboratory, and serves on an advisory board for Orlucent, Inc., VeriSkin, Inc., and Merck. John M. Kirkwood has been on an advisory board and\/or consultant for Amgen Inc., Ankyra Therapeutics, Axio Research, Becker Pharmaceutical, Bristol Myers Squibb, Checkmate Pharmaceuticals, DermTech, Elsevier, Fenix Group International, Harbour Biomed, Immunocore LLC, Intellisphere LLC, Iovance Biotherapeutics, IQVIA, Istari Oncology, Merck, Millennium Pharmaceuticals, Natera Inc., Novartis Pharmaceuticals, OncoCyte Corp., OncoSec Medical Inc., Pfizer, Replimune, Scopus BioPharma, and SR One Capital Management, and receives institutional research support from Amgen, Bristol Myers Squibb, Castle Biosciences, Checkmate Pharmaceuticals, Immvira Pharma Co., Immunocore LLC, Iovance Biotherapeutics, Lion Biotechnologies, Merck, Novartis Pharmaceuticals, and Schering-Plough, all unrelated to the content of this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}